Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Significant Growth in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) saw a large increase in short interest in September. As of September 15th, there was short interest totaling 400 shares, an increase of 187.8% from the August 31st total of 139 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Currently, 0.0% of the company’s stock are short sold.

Basilea Pharmaceutica Price Performance

BPMUF stock remained flat at $77.40 during trading hours on Friday. Basilea Pharmaceutica has a fifty-two week low of $59.29 and a fifty-two week high of $77.40. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. The business’s fifty day simple moving average is $71.07 and its 200-day simple moving average is $67.95.

About Basilea Pharmaceutica

Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology applications. The company was established in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland.

Basilea’s commercial portfolio includes Cresemba (isavuconazole), an antifungal used to treat invasive aspergillosis and invasive mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections.